This list is an analysis based on recent market events. It's not an investment recommendation.
About
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE111, LAE112, LAE113, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.
The current price of LAEKF is $0.73 USD — it has increased by +0% in the past 24 hours. Watch Laekna stock price performance more closely on the chart.
What is Laekna stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Laekna stocks are traded under the ticker LAEKF.
What is Laekna market cap?▼
Today Laekna has the market capitalization of 325.92M
When is the next Laekna earnings date?▼
Laekna is going to release the next earnings report on August 25, 2026.
What is Laekna revenue for the last year?▼
Laekna revenue for the last year amounts to 15.25M USD.
What is Laekna net income for the last year?▼
LAEKF net income for the last year is -32.34M USD.
How many employees does Laekna have?▼
As of August 23, 2026, the company has 83 employees.